Summary
Twenty-six patients with various solid tumors entered a Phase I trial with 4′ -Deoxydoxorubicin (Esorubicin, IMI-58), a new doxorubicin analogue. The drug was administered weekly i.v. for 3–4 weeks. Leukopenia proved to be dose limiting. The maximum tolerated dose (MTD) was reached at 20 mg/m2 weekly for 3 weeks. For Phase II trials, a weekly dose of 15 and 17.5 mg/m2 can be proposed for poor and good risk patients respectively. Non-hematologic toxicity was minimal. Phase II trials with this new anthracycline are warranted.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arcamone F, Penco S, Redaelli S, Hanessian S: Synthesis and antitumor activity of 4′-deoxydaunorubicin and 4′-deoxyadriamycin. J Med Chem 19:1424–1425, 1976
Casazza AM, Savi G, Pratesi G, Di Marco A: Antitumor ac tivity in mice of 4′-deoxydoxorubicin in comparison with doxorubicin. Eur J Cancer Clin Oncol 19:411–418, 1983
Guliani FC, Kaplan NO: New doxorubicin analogs active against doxorubicin-resistant colon tumor xenografts in the nude mouse. Cancer Res 40:4682–4687, 1980
Csazza AM, Di Marco A, Bonadonna G, Bonfante V, Bertazzoli C, Bellini O, Pratesi G, Sala L, Ballerini L: Effects of modifications in position 4 of the cromophore or in position 4′ of the amino-sugar, on the antitumor activity and toxicity of daunorubicin and doxorubicin. In ST Crooke and SD Reich (eds): Anthracycline: Current Status and New Developments. Academic Press, New York, 1980, pp 403–430
WHO Handbook for Reporting Results of Cancer Treatment. World Health Organization, Geneva, 1979
Rozencweig M, Von Hoff DD, Staquet MJ, Schein PS, Penta JS, Goldin A, Muggia FM, Freireich EJ, De Vita VT Jr: Animal toxicology for early clinical trials with anticancer agents. Cancer Clin Trials 4:21–28, 1981
Rozencweig M, Crespeigne N, Kenis Y: Phase I trial with 4′-deoxydoxorubicin (esorubicin). Inv New Drugs 1:309–313, 1983
Stanton GF, Wittes RE, Raymond V, Budman D, Shulman P, Kelsen D, Young CW: 4′-Deoxydoxorubicin (DXDX): a Phase I trial in patients (pts) with advanced cancer. Proc Am Assoc Cancer Res 24:153, 1983
Ferrari L, Rossi A, Brambilla C, Villani F, Bonfante V, Bonadonna G: Phase I study with 4-deoxydoxorubicin (deoxyDX). Proc Am Assoc Cancer Res 24:163, 1983
Salmon SE, Young L, Soehnlen B, Liu R: Antitumor activity of Esorubicin in Human tumor clonogenic assay with comparison to Doxorubicin. J Clin Oncol 2:282–286, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sessa, C., Bosia, L., Kaplan, S. et al. Phase I trial of 4′-deoxydoxorubicin given weekly. Invest New Drugs 2, 369–374 (1984). https://doi.org/10.1007/BF00171587
Issue Date:
DOI: https://doi.org/10.1007/BF00171587